Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board o.

Business Wire • Nov 20, 2025

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) establish a robust, complementary two-pronged approach for comprehensive Multiple Sclerosis (MS) disease a.

Business Wire • Nov 17, 2025

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

Quanterix Corporation ( QTRX ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Tom DeBourcy - Nephron Research LLC Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.

Seeking Alpha • Nov 11, 2025

Quanterix Releases Financial Results for the Third Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Equally important, we achieved key integration milestones from our Akoya.

Business Wire • Nov 10, 2025

Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Zacks Investment Research • Nov 10, 2025

Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results. Quanterix will issue a press release regarding its third quarter 2025 financial results prior to the conference call on Monday, November 10, 2025, after the market closes. The press release.

Business Wire • Nov 3, 2025

All You Need to Know About Quanterix (QTRX) Rating Upgrade to Buy

Quanterix (QTRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Oct 2, 2025

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanter.

Business Wire • Aug 21, 2025

Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX)

Quanterix (QTRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Aug 12, 2025

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be acc.

Business Wire • Aug 11, 2025